B-intervention	0	14	Identification
I-intervention	15	18	and
I-intervention	19	31	Preservation
I-intervention	32	34	of
I-intervention	35	38	Arm
I-intervention	39	48	Lymphatic
I-intervention	49	55	System
O	56	58	in
O	59	67	Axillary
O	68	78	Dissection
O	79	82	for
O	83	89	Breast
O	90	96	Cancer
O	97	99	to
O	100	106	Reduce
B-condition	107	110	Arm
I-condition	111	121	Lymphedema
O	122	128	Events
O	128	129	:
O	130	131	A
O	132	142	Randomized
O	143	151	Clinical
O	152	157	Trial
O	157	158	.

O	159	170	Controversy
O	171	173	in
O	174	182	axillary
O	183	190	reverse
O	191	198	mapping
O	199	201	in
O	202	210	axillary
O	211	216	lymph
O	217	221	node
O	222	232	dissection
O	233	234	(
O	234	238	ALND
O	238	239	)
O	240	248	possibly
O	249	256	results
O	257	261	from
O	262	272	incomplete
O	273	284	recognition
O	285	287	of
O	288	291	the
O	292	295	arm
O	296	305	lymphatic
O	306	312	system
O	313	314	(
O	314	317	ALS
O	317	318	)
O	319	322	and
O	323	326	its
O	327	337	compromise
O	338	340	to
O	341	352	oncological
O	353	359	safety
O	359	360	.

O	361	364	The
O	365	379	iDEntification
O	380	383	and
O	384	396	Preservation
O	397	399	of
O	400	403	ARm
O	404	413	lymphaTic
O	414	420	system
O	421	422	(
O	422	428	DEPART
O	428	429	)
O	430	439	technique
O	440	451	facilitates
O	452	460	complete
O	461	475	identification
O	476	478	of
O	479	482	ALS
O	482	483	;
O	484	493	therefore
O	493	494	,
O	495	498	its
O	499	502	use
O	503	506	may
O	507	515	decrease
O	516	519	the
O	520	530	occurrence
O	531	533	of
O	534	537	arm
O	538	548	lymphedema
O	548	549	.

O	550	554	This
O	555	560	study
O	561	566	aimed
O	567	569	to
O	570	577	examine
O	578	581	the
O	582	585	arm
O	586	596	lymphedema
O	597	601	rate
O	601	602	,
O	603	615	locoregional
O	616	626	recurrence
O	626	627	,
O	628	631	and
O	632	643	feasibility
O	644	646	to
O	647	654	perform
O	655	661	DEPART
O	662	664	in
O	665	669	ALND
O	669	670	.

O	671	679	Patients
O	680	684	from
O	685	693	February
O	694	698	2013
O	699	701	to
O	702	709	October
O	710	714	2017
O	715	719	from
O	720	723	two
O	724	732	tertiary
O	733	741	referral
O	742	749	centers
O	750	754	were
O	755	763	randomly
O	764	772	assigned
O	773	775	to
O	776	779	two
O	780	786	groups
O	786	787	.

O	788	790	In
O	791	794	the
O	795	800	study
O	801	806	group
O	806	807	,
O	808	819	indocyanine
O	820	825	green
O	826	829	and
O	830	839	methylene
O	840	844	blue
O	845	846	(
O	846	848	MB
O	848	849	)
O	850	854	were
O	855	863	utilized
O	864	866	to
O	867	875	identify
O	876	879	arm
O	880	888	sentinel
O	889	894	nodes
O	894	895	,
O	896	899	and
O	900	901	0
O	901	902	.
O	902	903	1
O	904	906	ml
O	907	909	MB
O	910	913	was
O	914	922	injected
O	923	927	into
O	928	931	the
O	932	935	arm
O	936	944	sentinel
O	945	950	nodes
O	951	953	to
O	954	960	reveal
O	961	964	the
O	965	975	subsequent
O	975	976	-
O	976	983	echelon
O	984	989	nodes
O	990	993	and
O	994	1004	lymphatics
O	1004	1005	.

O	1006	1011	Gross
O	1012	1015	arm
O	1016	1021	lymph
O	1022	1027	nodes
O	1028	1032	were
O	1033	1041	examined
O	1042	1044	by
O	1045	1059	intraoperative
O	1060	1067	partial
O	1068	1074	frozen
O	1075	1082	section
O	1083	1086	and
O	1087	1091	were
O	1092	1099	removed
O	1100	1102	if
O	1103	1111	positive
O	1111	1112	.

O	1113	1116	Arm
O	1117	1127	lymphedema
O	1127	1128	,
O	1129	1134	local
O	1135	1145	recurrence
O	1145	1146	,
O	1147	1155	regional
O	1156	1166	recurrence
O	1166	1167	,
O	1168	1171	and
O	1172	1179	distant
O	1180	1190	metastasis
O	1191	1195	were
O	1196	1204	recorded
O	1205	1207	at
O	1208	1217	different
O	1218	1224	follow
O	1224	1225	-
O	1225	1227	up
O	1228	1240	examinations
O	1240	1241	.

B-outcome	1242	1245	Arm
I-outcome	1246	1254	sentinel
I-outcome	1255	1260	nodes
O	1261	1265	were
O	1266	1276	identified
O	1277	1279	in
O	1280	1283	573
O	1284	1285	(
O	1285	1287	83
O	1287	1288	.
O	1288	1289	2
O	1289	1290	%
O	1290	1291	)
O	1292	1300	patients
O	1300	1301	.

B-outcome	1302	1312	Subsequent
I-outcome	1312	1313	-
I-outcome	1313	1320	echelon
I-outcome	1321	1326	nodes
I-outcome	1327	1330	and
I-outcome	1331	1341	lymphatics
O	1342	1346	were
O	1347	1357	visualized
O	1358	1360	in
O	1361	1364	558
O	1365	1366	(
O	1366	1368	97
O	1368	1369	.
O	1369	1370	4
O	1370	1371	%
O	1371	1372	)
O	1373	1381	patients
O	1381	1382	.

B-outcome	1383	1393	Metastatic
I-outcome	1394	1397	arm
I-outcome	1398	1403	nodes
O	1404	1408	were
O	1409	1419	identified
O	1420	1422	in
O	1423	1425	38
O	1426	1427	(
O	1427	1428	6
O	1428	1429	.
O	1429	1430	8
O	1430	1431	%
O	1431	1432	)
O	1433	1441	patients
O	1441	1442	.

O	1443	1446	The
B-outcome	1447	1450	arm
I-outcome	1451	1461	lymphedema
I-outcome	1462	1466	rate
O	1467	1470	was
B-iv-bin-percent	1471	1472	3
I-iv-bin-percent	1472	1473	.
I-iv-bin-percent	1473	1474	3
I-iv-bin-percent	1474	1475	%
O	1476	1477	(
B-iv-bin-abs	1477	1479	18
O	1479	1480	/
B-intervention-participants	1480	1483	543
O	1483	1484	)
O	1485	1487	in
O	1488	1491	the
O	1492	1497	study
O	1498	1503	group
O	1504	1510	versus
B-cv-bin-percent	1511	1513	15
I-cv-bin-percent	1513	1514	.
I-cv-bin-percent	1514	1515	3
I-cv-bin-percent	1515	1516	%
O	1517	1518	(
B-cv-bin-abs	1518	1520	99
O	1520	1521	/
B-control-participants	1521	1524	648
O	1524	1525	)
O	1526	1528	in
O	1529	1532	the
O	1533	1540	control
O	1541	1546	group
O	1547	1548	(
O	1548	1549	p
O	1550	1551	<
O	1552	1553	0
O	1553	1554	.
O	1554	1557	001
O	1557	1558	)
O	1559	1564	after
O	1565	1567	37
O	1567	1568	-
O	1568	1573	month
O	1574	1580	median
O	1581	1587	follow
O	1587	1588	-
O	1588	1590	up
O	1590	1591	.

B-outcome	1592	1600	Regional
I-outcome	1601	1611	recurrence
O	1612	1618	showed
O	1619	1621	no
O	1622	1632	difference
O	1633	1640	between
O	1641	1644	the
O	1645	1648	two
O	1649	1655	groups
O	1656	1657	(
B-iv-bin-percent	1657	1658	1
I-iv-bin-percent	1658	1659	.
I-iv-bin-percent	1659	1660	4
I-iv-bin-percent	1660	1661	%
O	1662	1665	and
B-cv-bin-percent	1666	1667	1
I-cv-bin-percent	1667	1668	.
I-cv-bin-percent	1668	1669	2
I-cv-bin-percent	1669	1670	%
O	1670	1671	,
O	1672	1684	respectively
O	1684	1685	)
O	1686	1687	(
O	1687	1688	p
O	1689	1690	=
O	1691	1692	0
O	1692	1693	.
O	1693	1696	392
O	1696	1697	)
O	1697	1698	.

O	1699	1705	DEPART
O	1706	1709	can
O	1710	1717	benefit
O	1718	1724	breast
O	1725	1731	cancer
O	1732	1740	patients
O	1741	1744	who
O	1745	1752	undergo
O	1753	1757	ALND
O	1757	1758	,
O	1759	1767	reducing
O	1768	1771	the
O	1772	1775	arm
O	1776	1786	lymphedema
O	1787	1791	rate
O	1792	1799	without
O	1800	1809	adversely
O	1810	1819	affecting
O	1820	1823	the
O	1824	1833	morbidity
O	1834	1836	of
O	1837	1845	regional
O	1846	1856	recurrence
O	1856	1857	.
